A securities class action has been filed against Anavex Life Sciences Corp. (AVXL) on behalf of purchasers of securities of Anavex Life Sciences Corp. between November 26, 2025 through August 28, 2026. This case has been filed in the USDC – SDNY.
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Anavex Life Sciences lacked adequate internal controls; (2) Anavex Life Sciences understated its potential regulatory challenges as a result of misconduct by former CEO Christopher Missling; and (3) as a result, defendants’ statements about Anavex Life Science’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.